Please login to the form below

Not currently logged in
Email:
Password:

Tremfya

This page shows the latest Tremfya news and features for those working in and with pharma, biotech and healthcare.

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

The psoriasis market is becoming increasingly crowded, with newcomers Taltz from Eli Lilly and Tremfya from Johnson &Johnson demonstrating dramatically improved outcomes in the condition.

Latest news

  • Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial

    Shifting expectations in psoriasis outcomes. Eli Lilly’s Taltz (ixekizumab) has outperformed Johnson &Johnson’s Tremfya (guselkumab) in a head-to-head post-marketing trial in patients with moderate-to-severe ... The clean sweep of primary and major

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    It adds that indirect comparisons suggest Skyrizi is likely to provide similar health benefits compared with J&J’s IL-23 inhibitor Tremfya (guselkumab) (which gained NICE recommendation a year ago) ... of Tremfya – however confidential price

  • Tremfya heads for filing in psoriatic arthritis Tremfya heads for filing in psoriatic arthritis

    Lilly's Talz sets pace with Humira head-to-head. J&J’s Tremfya has hit its primary endpoints in two phase 3 studies in psoriatic arthritis (PsA) putting it on ... J&J has unveiled top line data from the DISCOVER-1 and DISCOVER-2 phase 3 trials of

  • Latecomer Lilly preps its IL-23 drug for Crohn’s disease Latecomer Lilly preps its IL-23 drug for Crohn’s disease

    Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all ... Tremfya also has data suggesting it works in

  • Novartis claims first place for psoriasis drug Cosentyx in China Novartis claims first place for psoriasis drug Cosentyx in China

    makes it the market ahead of other interleukin-targeting rivals including Johnson &Johnson’s Tremfya (guselkumab), which are also en route to market. ... J&J is running a head-to-head trial of Tremfya versus Cosentyx in psoriasis to try to ramp up that

More from news
Approximately 7 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics